Comparison · NCT03151551-29b8221a
Ixekizumab vs Adalimumab: Number of Participants Who Answered Yes to Any 10 Questions in Columbia Suicide Severity Rating Scale (C-SSRS)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ixekizumab vs Adalimumab: Number of Participants Who Answered Yes to Any 10 Questions in Columbia Suicide Severity Rating Scale (C-SSRS). Trial comparisons, record NCT03151551-29b8221a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03151551-29b8221a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0318 | 0.0168 | 0.0593 | wilson | |
| Risk in group 2 | 0.0247 | 0.012 | 0.0502 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00707 | -0.0225 | 0.0374 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.29 | 0.486 | 3.4 | log | |
| Odds ratio, group 1 over group 2 | 1.3 | 0.476 | 3.53 | log | |
| Number needed to treat, for one more participant with the outcome on Ixekizumab than on Adalimumab | 142 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ixekizumab | 160 milligrams (mg) ixekizumab (IXE) given subcutaneously (SC) at baseline for all participants.~80 mg ixekizumab given once every 2 weeks (Q2W) SC from week 2 to week 12 and once every 4 weeks (Q4W) thereafter for participants with moderate-to-severe plaque Ps.~80 mg ixekizumab given SC Q4W starting week 4 for participants not meeting criteria for moderate-to-severe plaque Ps. | 9 | 283 | OG000 |
| Group 2 | Adalimumab | 80 mg adalimumab (ADA) given SC at baseline followed by 40 mg Q2W given SC starting week 1 for participants with moderate-to-severe plaque Ps.~40 mg adalimumab given Q2W SC at baseline followed by 40 mg Q2W starting at Week 2 given SC for participants not meeting criteria for moderate-to-severe plaque Ps. | 7 | 283 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- OTHER_PRE_SPECIFIED
- Title
- Number of Participants Who Answered Yes to Any 10 Questions in Columbia Suicide Severity Rating Scale (C-SSRS)
- Description
The C-SSRS is a scale that captures the occurrence, severity, and frequency of suicide-related ideations and behaviors during the assessment period.~1. Wish to be dead~2. Non-specific active suicidal thoughts~3. Active suicidal ideation with any methods (not plan) without intent to act~4. Active suicidal ideation with some intent to act, without specific plan~5. Active suicidal ideation with specific plan and intent~6. Preparatory acts or behavior~7. Aborted attempt~8. Interrupted attempt~9. Non-fatal suicide attempt~10. Completed suicide
- Time frame
- Week 52
- Population
All randomized participants. Per protocol and statistical analysis plan, the primary and secondary analysis were performed to compare all ixekizumab participants together versus all adalimumab participants together.
Source ClinicalTrials.gov
Trial
- Title
- A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
- NCT number
- NCT03151551
- Phases
- PHASE4
- Conditions
- Psoriatic Arthritis
- Interventions
- Ixekizumab, Adalimumab
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2019-04-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03151551?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03151551-29b8221a